Invivyd, Inc.
A biopharmaceutical company making monoclonal antibody medicines for viral diseases, Invivyd's only commercial product is PEMGARDA (pemivibart), a preventive antibody given to certain immunocompromised adults and teens at risk of COVID-19. It was founded in 2020 as Adagio Therapeutics, a spin-out of the antibody-discovery firm Adimab, and renamed Invivyd in 2022. The name hints at its mission of building antibodies that outpace fast-mutating viruses.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | 13G/APassive | 9.99% | 29.57M | Aug 14, 2026 |
| BVF INC/IL | 13G/APassive | 9.99% | 29.57M | Aug 14, 2026 |
| LAMPERT MARK N | 13G/APassive | 9.99% | 29.57M | Aug 14, 2026 |
| BVF GP HOLDINGS LLC | 13G/APassive | 9.2% | 27.22M | Aug 14, 2026 |
| Perceptive Advisors LLC | 13G/APassive | 6.3% | 18.49M | Aug 14, 2026 |
| Joseph Edelman | 13G/APassive | 6.3% | 18.49M | Aug 14, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. | 13G/APassive | 6.3% | 18.49M | Aug 14, 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 13G/APassive | 5.4% | 16.03M | Aug 14, 2026 |
| BVF I GP LLC | 13G/APassive | 5.4% | 16.03M | Aug 14, 2026 |
| BIOTECHNOLOGY VALUE FUND II LP | 13G/APassive | 3.8% | 11.18M | Aug 14, 2026 |